Bangalore: India-based Dr. Reddy's Laboratories has launched its montelukast sodium oral granules, a bioequivalent generic version of Singulair oral granules in the US market. The launch follows an approval by the US Food & Drug Administration (FDA) of Dr. Reddy's ANDA for montelukast sodium oral granules.
The Singulair oral granules brand had US sales of approximately $61 million for the most recent twelve months ending July 2012 according to IMS Health.
Dr. Reddy's Montelukast Sodium Oral Granules in 4 mg will be available in unit dosage package of 30.
